|
Drugs because of its life- related characteristics , determine its special purpose , quality , timeliness , procurement and sales methods , medicines are also recognized worldwide as the most stringent controls one of the commodities . According to China 's procurement of drugs for medical institutions must be required by pharmaceutical wholesale business links , of many low-quality , low-tech manufacturers to compete harsh means each circulation have also profiteering secret operations in the country \etc. the policy drawbacks fueled interest mechanism driven pricing of drugs is increasing , serious harm to people's economic life and physical and mental health . Hold down prices , the state has adopted a series of rectification measures , civil , there have been some positive impact drugs at high prices purchasing their drawbacks , but overall , a temporary solution . This paper argues that the fundamental way to solve the drugs artificially high pricing is the implementation of the doctors , drug separately , excluding hospitals, doctors completely separated from the outside in the pharmaceutical distribution process , so that the interests of the pharmaceutical sales and business interests of the hospital . Accountability mechanisms to establish drug pricing established by medical experts , experts in economics , clinical experts consisting of drug pricing committee. Sound integrity supervision and restraint mechanisms , and increase the reputation of punishment . Implementation of new health insurance model , to eliminate hospital abuse prescribe , only to open the high-priced drugs , to hold down prices contributed to the vulnerability . Further rectify the pharmaceutical market , to speed up the construction of information technology , and establish a price monitoring system throughout the country to promote the effective combination of law and self-regulation , to achieve high efficiency and low cost of the drugs in circulation . Of course , the process of reform must be accompanied by all kinds of resistance and new problems , but as long as the State Pharmaceutical separate related policy implementation can fundamentally avoid the low level of competition , in order to guide the pharmaceutical companies to optimize the product structure , improve the quality of medicines , reduce production costs , jumped out of the vicious competition in the swamp , and promote the healthy development of the pharmaceutical companies . Only a thorough , comprehensive institutional change in order to realize the rational regression of the medical expenses .
|